<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231526</url>
  </required_header>
  <id_info>
    <org_study_id>IRB19-1411</org_study_id>
    <nct_id>NCT04231526</nct_id>
  </id_info>
  <brief_title>Pembrolizumab in Early Stage Colon Cancer</brief_title>
  <official_title>A Window of Opportunity Study of Pembrolizumab in Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will gather information on the safety and effectiveness of pembrolizumab, an&#xD;
      immunotherapy drug. The purpose of this study is to target early stage colon cancer before it&#xD;
      has developed resistance to immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2020</start_date>
  <completion_date type="Anticipated">March 19, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 19, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the feasibility of neoadjuvant pembrolizumab in early stage colon cancer</measure>
    <time_frame>14 months</time_frame>
    <description>Measured using RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the tumor response in early stage colon cancer after neoadjuvant pembrolizumab</measure>
    <time_frame>14 months</time_frame>
    <description>Measured using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the immune response in early stage colon cancer after neoadjuvant pembrolizumab</measure>
    <time_frame>14 months</time_frame>
    <description>Measured using RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>ARM A - Pembrolizumab + Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B - Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>2 cycles of neoadjuvant pembrolizumab (200mg IV every 21 days)</description>
    <arm_group_label>ARM A - Pembrolizumab + Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Standard of care surgery</description>
    <arm_group_label>ARM A - Pembrolizumab + Surgery</arm_group_label>
    <arm_group_label>ARM B - Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have histologically confirmed colon adenocarcinoma.&#xD;
&#xD;
          2. No prior chemotherapy, targeted therapy, or immunotherapy for colon cancer.&#xD;
&#xD;
          3. Deemed to have surgically resectable disease.&#xD;
&#xD;
          4. Archival tissue block containing colon adenocarcinoma must be confirmed available&#xD;
             prior to enrollment. MSI testing should be obtained prior to starting therapy.&#xD;
&#xD;
          5. Be willing and able to provide written informed consent/assent for the trial.&#xD;
&#xD;
          6. Be 18 years of age or older on day of signing informed consent.&#xD;
&#xD;
          7. Have a measurable primary lesion by lower endoscopy or CT-imaging with a diameter of 1&#xD;
             or more centimeters.&#xD;
&#xD;
          8. Have a performance status of 0 or 1 on the ECOG Performance Scale.&#xD;
&#xD;
          9. Have no histologically confirmed disseminated disease by CT or PET-CT staging.&#xD;
&#xD;
         10. Male participant must agree to use a contraception as detailed in Appendix 3 of this&#xD;
             protocol during the treatment period and for at least 120 days after the last dose of&#xD;
             study treatment and refrain from donating sperm during this period.&#xD;
&#xD;
         11. A female participant is eligible to participate if she is not pregnant (see Appendix&#xD;
             3), not breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
               1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR&#xD;
&#xD;
               2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the&#xD;
                  treatment period and for at least 90 days after the last dose of study treatment.&#xD;
&#xD;
         12. Demonstrate adequate organ function as defined below. All screening labs should be&#xD;
             performed within 14 days of treatment initiation.&#xD;
&#xD;
               -  Adequate Organ Function Laboratory Values&#xD;
&#xD;
                    -  Hematological&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) - ≥1500/µL&#xD;
&#xD;
               -  Platelets - ≥100 000/µL&#xD;
&#xD;
               -  Hemoglobin - ≥7.0 g/dL or ≥5.6 mmol/La&#xD;
&#xD;
                    -  Renal&#xD;
&#xD;
               -  Creatinine OR measured or calculated creatinine clearance (GFR can also be used&#xD;
                  in place of creatinine or CrCl) - ≤1.5 × ULN OR&#xD;
&#xD;
                    -  30 mL/min for participant with creatinine levels &gt;1.5 × institutional ULN&#xD;
&#xD;
                         -  Hepatic&#xD;
&#xD;
               -  Total bilirubin - ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total&#xD;
                  bilirubin levels &gt;1.5 × ULN&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) - ≤2.5 × ULN (≤5 × ULN for participants with liver&#xD;
                  metastases)&#xD;
&#xD;
                    -  Coagulation&#xD;
&#xD;
               -  International normalized ratio (INR) OR prothrombin time (PT)/ Activated partial&#xD;
                  thromboplastin time (aPTT) - ≤1.5 × ULN unless participant is receiving&#xD;
                  anticoagulant therapy as long as PT or aPTT is within therapeutic range of&#xD;
                  intended use of anticoagulants&#xD;
&#xD;
                    -  ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase);&#xD;
                       AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic&#xD;
                       transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal.&#xD;
&#xD;
               -  Criteria must be met without erythropoietin dependency and without packed red&#xD;
                  blood cell (pRBC) transfusion within last 2 weeks.&#xD;
&#xD;
               -  Creatinine clearance (CrCl) should be calculated per institutional standard.&#xD;
                  Note: This table includes eligibility-defining laboratory value requirements for&#xD;
                  treatment; laboratory value requirements should be adapted according to local&#xD;
                  regulations and guidelines for the administration of specific chemotherapies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A WOCBP who has a positive urine pregnancy test during screening (see Appendix 3). If&#xD;
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test&#xD;
             will be required.&#xD;
&#xD;
          2. Is currently participating and receiving study therapy or has participated in a study&#xD;
             of an investigational agent and received study therapy or used an investigational&#xD;
             device within 4 weeks of the first dose of treatment.&#xD;
&#xD;
          3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
          4. Has a known history of active TB (Bacillus Tuberculosis)&#xD;
&#xD;
          5. Known hypersensitivity to pembrolizumab or any of its excipients.&#xD;
&#xD;
          6. If subject received major surgery, they must have recovered adequately from the&#xD;
             toxicity and/or complications from the intervention prior to starting therapy.&#xD;
&#xD;
          7. Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy or in situ cervical cancer.&#xD;
&#xD;
          8. Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
          9. Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
         10. Has a history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis.&#xD;
&#xD;
         11. Has an active infection requiring systemic therapy.&#xD;
&#xD;
         12. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         13. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         14. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.&#xD;
&#xD;
         15. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
         16. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
         17. Has received a live vaccine within 30 days of planned start of study therapy.&#xD;
&#xD;
         18. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the study, starting with the screening visit through 120 days&#xD;
             after the last dose of trial treatment.&#xD;
&#xD;
         19. Has complications from colon cancer including but not limited to organ fistulas,&#xD;
             bleeding and obstruction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Catenacci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Catenacci, MD</last_name>
    <phone>773-702-2042</phone>
    <email>dcatenacci@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Of Chicago Medicine Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Catenacci, MD</last_name>
      <phone>773-702-2042</phone>
      <email>dcatenacci@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Catenacci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Eaton</last_name>
      <phone>217-876-4758</phone>
      <email>eaton.casey@mhsil.com</email>
    </contact>
    <contact_backup>
      <last_name>Dianna Richardson</last_name>
      <phone>217-876-4760</phone>
      <email>richardson.dinna@mhsil.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Wade, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

